Respiratory syncytial virus (RSV) causes respiratory illness among persons of all age groups. RSV is one of the most common causes of childhood illness and is the most common cause of hospitalization in infants. It also causes severe disease and hospitalizations in older adults, especially those with certain chronic medical conditions.
Abrysvo vaccine is now FDA-approved as a single intramuscular dose (0.5 mL) for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged ≥ 18 years (previously aged ≥ 60 years) who are at increased risk of severe consequences due to underlying medical conditions (e.g., chronic obstructive pulmonary disease, asthma, heart failure, and diabetes). Abrysvo is also approved for active vaccination of pregnant women (32-36 weeks of gestation) for the prevention of LRTD caused by RSV in infants from birth through age 6 months.
